Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrunâ€™s fortune. Dr. Belldegrun, a physician,   Kite Pharma, a company that could be the first to market next year with a highly anticipated new immunotherapy treatment. But even without a product, Dr. Belldegrun has struck gold. His stock in Kite is worth about $170 million. 